StreetInsider.com News Articles

Form 8-K REVELATION BIOSCIENCES, For: Jun 01

Mon, 01 Jun 2026 17:27:00 -0400

si-local-file:///var/storage/secattach/20260601/26585158.html

Form 8-K REVELATION BIOSCIENCES, For: Jun 01

Mon, 01 Jun 2026 17:27:00 -0400

si-local-file:///var/storage/secattach/20260601/26585158.html

Revelation Biosciences adds two experts to kidney injury advisory board

Mon, 01 Jun 2026 09:00:13 -0400

Revelation Biosciences, Inc. (NASDAQ: REVB) announced the addition of two medical experts to its Acute Kidney Injury Advisory Board ahead of a planned Phase 2/3 clinical trial for its drug candidate Gemini.

The company added Dr. Peter Pickkers, Professor of Intensive Care Medicine at Radboud University Medical Center in the Netherlands, and Dr. Lui Forni, Professor of intensive care medicine at Royal Surrey County Hospital NHS Foundation Trust. Both physicians specialize in nephrology and critical care medicine.

Dr. Pickkers focuses his research on immune response modulation, sepsis, and organ dysfunction, particularly kidney-related conditions. He has supervised 28 doctoral candidates and leads research

Revelation Biosciences Expands Acute Kidney Injury Advisory Board

Mon, 01 Jun 2026 09:00:00 -0400

SAN DIEGO, CA / ACCESS Newswire / June 1, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today announced the expansion of its Acute Kidney Injury (AKI) Advisory Board, with the addition of two new members, Dr. Peter Pickkers and Dr. Lui Forni, ahead of its upcoming Phase 2/3 clinical trial. The distinguished panel comprises internationally recognized nephrologists and critical care physicians who will guide the company's clinical strategy, monitor trial progress,

Revelation Biosciences Expands Acute Kidney Injury Advisory Board

Mon, 01 Jun 2026 09:00:00 -0400

Form SCHEDULE 13G REVELATION BIOSCIENCES, Filed by: ARMISTICE CAPITAL, LLC

Fri, 15 May 2026 11:35:00 -0400

si-local-file:///var/storage/secattach/20260515/26502275.html

Form SCHEDULE 13G REVELATION BIOSCIENCES, Filed by: ARMISTICE CAPITAL, LLC

Fri, 15 May 2026 11:35:00 -0400

si-local-file:///var/storage/secattach/20260515/26502275.html

Form DEF 14A REVELATION BIOSCIENCES, For: Jun 24

Mon, 11 May 2026 09:56:00 -0400

si-local-file:///var/storage/secattach/20260511/26466526.html

Form DEF 14A REVELATION BIOSCIENCES, For: Jun 24

Mon, 11 May 2026 09:56:00 -0400

si-local-file:///var/storage/secattach/20260511/26466526.html

Revelation Biosciences plans Phase 2/3 study for kidney injury drug

Mon, 11 May 2026 09:02:08 -0400

Revelation Biosciences, Inc. (NASDAQ: REVB) announced plans to begin a Phase 2/3 adaptive design clinical study for its drug candidate Gemini in the fourth quarter of 2026, according to a corporate update letter to stockholders.

The company reported reaching agreements with the FDA in December 2025 regarding the approval pathway for Gemini as a treatment for acute kidney injury (AKI). The FDA agreed that positive data from a single well-controlled Phase 2/3 study comprising approximately 300 patients can be submitted as part of a new drug application.

The study will use a composite endpoint comprising death and dialysis. The adaptive design allows

Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders

Mon, 11 May 2026 09:00:00 -0400

SAN DIEGO, CA / ACCESS Newswire / May 11, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, released its 2026 annual meeting proxy materials today, which included a corporate update letter to its stockholders from James Rolke, Chief Executive Officer of Revelation, the body of the letter follows.

Dear Stockholders:

As you know, Revelation is a clinical stage company working to develop a high-impact, potentially lifesaving drug called Gemini for the treatment

Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders

Mon, 11 May 2026 09:00:00 -0400

Dear Stockholders:

As you know, Revelation is a clinical stage company working to develop a high-impact, potentially lifesaving drug called Gemini for the treatment

Form ARS REVELATION BIOSCIENCES, For: May 11

Mon, 11 May 2026 08:45:00 -0400

si-local-file:///var/storage/secattach/20260511/26465894.html

Form ARS REVELATION BIOSCIENCES, For: May 11

Mon, 11 May 2026 08:45:00 -0400

si-local-file:///var/storage/secattach/20260511/26465894.html

Form 8-K REVELATION BIOSCIENCES, For: May 07

Thu, 07 May 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260507/26454005.html

Form 8-K REVELATION BIOSCIENCES, For: May 07

Thu, 07 May 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260507/26454005.html

Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026

Thu, 07 May 2026 16:15:00 -0400

SAN DIEGO, CA / ACCESS Newswire / May 7, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today reported its financial results for the three months ended March 31, 2026.

Corporate Highlights

Announced agreement with FDA on a single adaptive Phase 2/3 study for approval of Gemini for treatment of acute kidney injury
Received net proceeds of $6.7 million from warrant inducement in January 2026
Participated in a fireside chat at the 38th

Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026

Thu, 07 May 2026 16:15:00 -0400

SAN DIEGO, CA / ACCESS Newswire / May 7, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today reported its financial results for the three months ended March 31, 2026.

Corporate Highlights

Announced agreement with FDA on a single adaptive Phase 2/3 study for approval of Gemini for treatment of acute kidney injury
Received net proceeds of $6.7 million from warrant inducement in January 2026
Participated in a fireside chat at the 38th